NCT06637423

A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027)

Public trial-level signal summary for this oncology Phase 2 record.

Record overview

Status and phase

Status: RECRUITING

Phase: PHASE1, PHASE2

Sponsor: Merck Sharp & Dohme LLC

Condition: Non-Muscle Invasive Bladder Cancer

Signal summary

Status signal: Low Signal

Timeline signals: long_recruitment_duration_signal

Results signal: Low Signal

Operational burden: None

Stopped reason

No stop reason available in the current public record.